Population Pharmacokinetics of Imatinib in CML Patients in Iran

• Status: Terminated
• Trial end date: 2017-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine population Pharmacokinetics and differences and variation of pharmacokinetics parameters of Imatinib as a tyrosine kinase inhibitor in treatment of chronic myeloid leukemia patients in Iranian population.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kerman University of Medical Sciences
• Treatments: Imatinib Mesylate

Criteria

Inclusion Criteria:

• patient in chronic phase of myeloid leukemia

• no liver and renal failure

Exclusion Criteria:

• multiple dug treatment

• previous treatment of interferon

• patients in blast or accelerated phase